title: Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life.
abstract: This study was designed to assess the immunogenicity of a vaccine combining diphtheria and tetanus toxoids, acellular pertussis vaccine, and inactivated poliovirus vaccine reconstituting Haemophilus influenzae type b polysaccharide conjugated to tetanus protein (DTaP-IPV//PRP-T; Pasteur Mérieux Connaught, Lyon, France) administered simultaneously in association with hepatitis B vaccine (RECOMBIVAX (¿trade mark omitted¿) Merck, Sharp & Dohme, West Point, PA, USA) for the primary immunization of infants. The vaccines were administered at two, three and four months of age. One hundred and sixty-two healthy infants, aged 8-10 weeks, were enrolled in the study. Blood samples were taken before the first dose and 4 weeks after the third dose. The infants were observed for 15 minutes after vaccination for any immediate reaction. Adverse events requiring a medical consultation were recorded by the parents in a diary over the 7 days following vaccination. Four weeks after the third immunization, the percentages of infants fulfilling seroconversion criteria were 98.9% for pertussis toxin, 95.9% for filamentous haemagglutinin, 100.0% for tetanus, 100.0% for diphtheria, 99.3% for poliovirus type 1, 100.0% for both poliovirus types 2 and 3, 98.0% for Haemophilus influenzae type b, and 100% for hepatitis B surface antigen. No vaccine-related serious adverse event was reported. The simultaneous administration of DTaP-IPV//PRP-T and hepatitis B vaccines at two, three and four months of age yielded clinically satisfactory immune responses to all antigens compared with historical controls and gave a good safety profile.
authors.affiliation: Hacettepe University School of Medicine, Pediatric Infectious Diseases Unit, Ankara, Turkey.
authors.forename: G
authors.initials: G
authors.lastname: Kanra
authors.forename: T
authors.initials: T
authors.lastname: Silier
authors.forename: K
authors.initials: K
authors.lastname: Yurdakök
authors.forename: T
authors.initials: T
authors.lastname: Yavuz
authors.forename: S
authors.initials: S
authors.lastname: Baskan
authors.forename: B
authors.initials: B
authors.lastname: Ulukol
authors.forename: M
authors.initials: M
authors.lastname: Ceyhan
authors.forename: E
authors.initials: E
authors.lastname: Ozmert
authors.forename: F
authors.initials: F
authors.lastname: Türkay
authors.forename: T
authors.initials: T
authors.lastname: Pehlivan
mesh_terms: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D005260:Female; D018073:Haemophilus Vaccines; D017325:Hepatitis B Vaccines; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D011054:Poliovirus Vaccine, Inactivated; D014421:Turkey; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic; D014944:World Health Organization
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D017325:Hepatitis B Vaccines; D011054:Poliovirus Vaccine, Inactivated; C075655:Recombivax HB; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic; C122182:diphtheria-tetanus-acellular pertussis-Hib-hepatitis B vaccine